-
Creative Bioarray Enlarged Its Primary Cells Variety
Oct 25, 2016, 00:21 AM by Michael CroftLONG ISLAND CITY, NY, UNITED STATES - Oct 24, 2016 - After transferred its core products line into cells, Creative Bioarray is endeavoring to enlarge its cells products variety to become a one-stop cells and related kits or tools supplier in USA, which doesnt mean the company sold a narrow range of cells before the strategy launchFull story -
Benchling Announces $7M in New Funding Led by Thrive Capital
Oct 24, 2016, 13:04 PM by Michael CroftSAN FRANCISCO, CA, UNITED STATES - Oct 24, 2016 - Benchling, the next-generation life science R&D software company, announced that is has raised $7 million in new fundingFull story -
Research at MDI Biological Laboratory Examines Role of Early-Life Stress in Adult Illness
Oct 24, 2016, 12:47 PM by Michael CroftBAR HARBOR, ME - Oct 24, 2016 - Scientists have long known that chronic exposure to psychosocial stress early in life can lead to an increased vulnerability later in life to diseases linked to immune dysfunction and chronic inflammation, including arthritis, asthma, cancer, diabetes, heart disease and even mental illnessFull story -
The Trials of Juno
Oct 24, 2016, 09:28 AM by Michael CroftThe Economist | Juno Therapeutics, a young biotech firm focused on cancer, promises both risk and reward with its attempt to master the T-cell. The firm is on the forefront of the most promising area of cancer treatments in decades.Full story -
Cenduit Participates in QuintilesIMS Webinar to Share Tips on Continuous Glucose Monitoring (CGM) in Clinical Trials
Oct 24, 2016, 09:07 AM by Michael CroftRESEARCH TRIANGLE PARK, NC, UNITED STATES - Oct 24, 2016 - Cenduit, a joint venture between QuintilesIMS and Thermo Fisher Scientific, is participating in a free webinar hosted by QuintilesIMS, where expert guest speakers will highlight regulatory trends, technology innovation and industry perspectives surrounding Continuous Glucose Monitoring (CGM) to help sponsors develop smarter diabetes clinical trialsFull story -
New Advance in Peptides Has Raised Increasing Attention
Oct 24, 2016, 02:46 AM by Michael CroftSHIRLEY, NY - Oct 24, 2016 - As is known, it has long been a dream in medicine and pharmacy to use peptides as drugs. The driving force for such application is based on the ability of these compounds to improve the antibodies in the bodyFull story -
Welcome to DNA.Land: Trait Prediction, A Breast Cancer Research Collaboration, And a Facebook Group
Oct 21, 2016, 09:50 AM by Michael CroftFull storyBio-IT World “We’ve already entered the era of ubiquitous genetic information.” says Yaniv Erlich, so he and colleagues have built DNA.Land, to crowdsource these available genomes from individuals. A ticker on the DNA.Land website counts almost 32,000 genomes deposited into DNA.Land so far. The project recently launched a collaboration with the National Breast Cancer Coalition and has started offering trait predictions.
-
Hydrolases Products Line Has Been Updated By Scientists in Creative Enzymes
Oct 20, 2016, 23:44 PM by Michael CroftSHIRLEY, NY - Oct 21, 2016 - October 20, 2016, experienced scientists in Creative Enzymes introduced a part of newly-updated products belonging to hydrolases products, which symbolized the beginning of developing hydrolases products in Creative EnzymesFull story -
Illumina Builds Africa GWAS Chip With H3Africa Initiative
Oct 20, 2016, 13:45 PM by Michael CroftBio-IT World | Last week, Illumina announced that it is creating an array for genome-wide association studies (GWAS) by the Human Heredity and Health in Africa (H3Africa) Initiative. The array—which isn’t available yet—will be include 2.5 million variations of specific interest to African populations.Full story -
How Spinal Decompression Stops The Pain, Strengthens The Back And Restores Functional Use
Oct 20, 2016, 13:38 PM by Michael CroftWILMINGTON, NC, UNITED STATES - Oct 20, 2016 - As mentioned earlier in this report, the procedure provides relief of pain and symptoms associated with herniated discs, bulging or protruding intervertebral discs, degenerative disc disease, sciatica and chronic painFull story -
Perlara Signs Rare Disease Pact with Novartis
Oct 20, 2016, 10:48 AM by Michael CroftChemical & Engineering News | In a critical validation for a biotech firm espousing an unusual business model, Perlara has struck a deal to develop lysosomal storage disorder treatments with Novartis. The big pharma company will also make an undisclosed investment in the rare-disease-focused firm.Full story -
News and Notes from ASHG 2016
Oct 20, 2016, 10:30 AM by Michael CroftBio-IT World News Brief | The American Society of Human Genetics annual meeting is currently underway in Vancouver, Canada. Here are some of the product news and company announcements released so far this week. Highlights include the Genome Aggregation Database, Illumina’s contribution to ClinVar, BabySeq news, and more.Full story -
High diagnostic yields by Sapientia in 100,000 Genomes Project
Oct 20, 2016, 10:09 AM by Michael CroftCAMBRIDGE, UNITED KINGDOM - Oct 20, 2016 - Congenica, a clinical interpretation partner for the UK 100,000 Genomes Project, has announced that its whole genome analysis platform Sapientia is detecting clinically relevant variants in over 35% of diagnostics reports returned to the NHS Genomic Medicine Centres (GMCs) for the Pilot and Main Phase studiesFull story -
Pine Biotech and Medexprim Selected as Grand Prize Winners in the 2016 Pistoia Alliance President’s Startup Challenge
Oct 20, 2016, 09:32 AM by Michael CroftBOSTON, MA, USA - Oct 19, 2016 - The Pistoia Alliance, a global, not for profit alliance that works to lower barriers to innovation in life sciences R&D, has today announced that Pine Biotech and Medexprim have been selected as the grand prize winners of its 2016 Presidents Startup ChallengeFull story -
Elsevier's R&D Solutions Welcomes Four Biotech Start-Ups to the Hive
Oct 20, 2016, 09:29 AM by Michael CroftNEW YORK, NY, UNITED KINGDOM - Oct 20, 2016 - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that four start-up companies have been selected for The Hive, Elsevier's new incubator project for biotech and pharmaceutical start-up firmsFull story -
Spinal Decompression Therapy – Serving Wilmington, Leland & Hampstead NC
Oct 19, 2016, 16:38 PM by Michael CroftWILMINGTON, NC, UNITED STATES - Oct 20, 2016 - Decompression relieves pressure that builds up on the discs and nerves. The task of relieving pain comes about as a result of drawing areas of herniated disc back into placeFull story -
Elsevier Launches New Release of Reaxys to Enable Chemists to Find the Shortest Path From Question to Answer
Oct 19, 2016, 12:54 PM by Michael CroftNEW YORK, NY - Oct 19, 2016 - - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of the new release of Reaxys, a chemistry research experience that delivers relevant literature and data more than twice as fast as any other solutionFull story -
Elsevier Opens Second Reaxys ChemSearch Challenge, Inviting Entrants to Compete in Solving Chemistry Conundrums
Oct 19, 2016, 12:49 PM by Michael CroftNEW YORK, NY - Oct 19, 2016 - Elsevier, a world-leading provider of scientific, technical and medical information products and services, has today announced that the 2016 Reaxys ChemSearch Challenge is now live, following its successful debut last yearFull story -
Discovery of Carbon Storage Signaling Mechanism in Algae Offers New Potential for Sustainable Biofuel Production
Oct 19, 2016, 09:52 AM by Michael CroftST. LOUIS, MO, UNITED STATES - Oct 19, 2016 - James Umen, Ph.D., associate member at Donald Danforth Plant Science Center, and colleagues have discovered a way to make algae better oil producers without sacrificing growthFull story -
The Cure for Cancer Is Data—Mountains of Data
Oct 19, 2016, 09:38 AM by Michael CroftWIRED | We must access genetic info from millions of cancer patients to make the connections necessary to battle the disease. It won't be easy, but Eric Schadt believes we can do it.Full story